John Radford

29.6k total citations · 5 hit papers
377 papers, 15.7k citations indexed

About

John Radford is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Radford has authored 377 papers receiving a total of 15.7k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Pathology and Forensic Medicine, 167 papers in Oncology and 99 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Radford's work include Lymphoma Diagnosis and Treatment (245 papers), Chronic Lymphocytic Leukemia Research (90 papers) and Lung Cancer Treatments and Mutations (78 papers). John Radford is often cited by papers focused on Lymphoma Diagnosis and Treatment (245 papers), Chronic Lymphocytic Leukemia Research (90 papers) and Lung Cancer Treatments and Mutations (78 papers). John Radford collaborates with scholars based in United Kingdom, United States and Italy. John Radford's co-authors include Peter Johnson, D. Crowther, A. Z. S. Rohatiner, Ruth Pettengell, David Cunningham, David C. Linch, Barry W. Hancock, Pier Luigi Zinzani, Jean‐Yves Blay and Martin Harris and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

John Radford

362 papers receiving 15.2k citations

Hit Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatme... 1998 2026 2007 2016 1998 2017 2015 2013 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    1998 724 citations Peter Johnson, John Radford et al. Blood profile →
  2. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
    2017 694 citations Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology profile →
  3. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
    2015 407 citations John Radford, Ruth Pettengell et al. profile →
  4. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    2013 357 citations Kirit M. Ardeshna, John Radford et al. profile →
  5. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
    2021 264 citations Paolo F. Caimi, Kirit M. Ardeshna et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Radford United Kingdom 65 8.8k 7.8k 3.0k 2.9k 2.4k 377 15.7k
Sandra J. Horning United States 62 13.9k 1.6× 10.4k 1.3× 4.5k 1.5× 3.1k 1.1× 4.1k 1.7× 228 19.4k
Craig H. Moskowitz United States 56 10.4k 1.2× 8.8k 1.1× 3.2k 1.1× 1.6k 0.6× 4.1k 1.7× 304 14.2k
Jonathan W. Friedberg United States 61 9.1k 1.0× 6.5k 0.8× 3.8k 1.3× 1.3k 0.5× 2.4k 1.0× 393 12.7k
John P. Leonard United States 67 9.4k 1.1× 6.7k 0.9× 5.2k 1.8× 1.8k 0.6× 1.6k 0.7× 490 17.1k
Pinuccia Valagussa Italy 68 6.5k 0.7× 11.8k 1.5× 1.4k 0.5× 3.6k 1.3× 1.3k 0.6× 256 19.0k
F. Anthony Greco United States 66 4.2k 0.5× 9.4k 1.2× 1.3k 0.4× 4.1k 1.4× 1.7k 0.7× 491 16.3k
Thierry Philip France 52 4.6k 0.5× 4.8k 0.6× 1.9k 0.7× 3.3k 1.1× 3.2k 1.3× 277 12.0k
Richard Sposto United States 67 2.8k 0.3× 3.4k 0.4× 4.2k 1.4× 2.0k 0.7× 3.9k 1.6× 282 13.4k
Maria Alma Rodriguez United States 51 6.2k 0.7× 4.8k 0.6× 2.3k 0.8× 1.2k 0.4× 1.8k 0.8× 329 9.0k
Andrew Jack United Kingdom 48 6.2k 0.7× 3.8k 0.5× 3.8k 1.3× 857 0.3× 1.6k 0.7× 206 9.9k

Countries citing papers authored by John Radford

Since Specialization
Citations

This map shows the geographic impact of John Radford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Radford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Radford more than expected).

Fields of papers citing papers by John Radford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Radford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Radford. The network helps show where John Radford may publish in the future.

Co-authorship network of co-authors of John Radford

This figure shows the co-authorship network connecting the top 25 collaborators of John Radford. A scholar is included among the top collaborators of John Radford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Radford. John Radford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiu, Arthur, Genevieve Parker, John Radford, et al.. (2025). The Incretin Effect of Yerba Maté (Ilex paraguariensis) Is Partially Dependent on Gut-Mediated Metabolism of Ferulic Acid. Nutrients. 17(4). 625–625. 1 indexed citations
2.
Luminari, Stefano, Alexander Fosså, Judith Trotman, et al.. (2023). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology. 42(1). 13–18. 16 indexed citations
3.
Ghione, Paola, M. Lia Palomba, Anik R. Patel, et al.. (2022). Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 140(8). 851–860. 35 indexed citations
4.
Advani, Ranjana H., Tetiana Skrypets, Monica Civallero, et al.. (2021). Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 138(3). 213–220. 60 indexed citations
5.
6.
Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations
7.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations
8.
Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132. 694 indexed citations breakdown →
9.
10.
Vitolo, Umberto, Franck Morschhauser, John Radford, et al.. (2008). CONSOLIDATION OF FIRST REMISSION WITH 90Y-IBRITUMOMAB TIUXETAN IN ADVANCED FOLLICULAR NON-HODGKIN'S LYMPHOMA (FL): RESULTS FROM THE PHASE 3 RANDOMIZED FIRST-LINE INDOLENT TRIAL (FIT). Annals of Oncology. 19. 231–232. 1 indexed citations
11.
Morschhauser, Franck, John Radford, Achiel Van Hoof, et al.. (2008). Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. Journal of Clinical Oncology. 26(32). 5156–5164. 314 indexed citations
12.
Christie, David, Elías Gracia, M. Gospodarowicz, et al.. (2007). Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group. Haematologica. 92. 3 indexed citations
13.
14.
Williams, M. V., et al.. (2007). Selection of patients for minimal initial chemotherapy (MIC): The impact of Hasenclever score on outcome in patients receiving MIC and involved field radiotherapy for clinical stage IA/IIA supra-diaphragmatic Hodgkin lymphoma in the UKNCRI LY07 trial. Haematologica. 92(5). 52–52. 4 indexed citations
15.
Chanudet, Estelle, Chris M. Bacon, AC Wotherspoon, et al.. (2006). Chlamydia psittaci is variably associated with ocular MALT lymphoma in different geographical regions. UCL Discovery (University College London). 2 indexed citations
16.
Hagenbeek, Anton, et al.. (2005). A novel fully human anti-CD20 monoclonal antibody: First clinical results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphoma. Annals of Oncology. 16. 71–71. 3 indexed citations
17.
Hancock, Bruno C., John Radford, M.H. Cullen, et al.. (2004). Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).. British Journal of Cancer. 91. 1 indexed citations
18.
Cesne, Axel Le, Ian Judson, John Radford, et al.. (2000). Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial. Annals of Oncology. 11. 126–126. 9 indexed citations
19.
Pool, C.W., et al.. (1999). Follow-up (FU) policy after treatment for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL); The patients view. British Journal of Cancer. 80. 20–20. 16 indexed citations
20.
Pettengell, Ruth, et al.. (1992). Peripheral blood progenitor cells PBPC for haemopoietic rescue for poor prognosis high grade NHL. Research Explorer (The University of Manchester). 33. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra J. Horning Breakdown of academic impact, for papers by Craig H. Moskowitz Breakdown of academic impact, for papers by Jonathan W. Friedberg Breakdown of academic impact, for papers by John P. Leonard Breakdown of academic impact, for papers by Pinuccia Valagussa Breakdown of academic impact, for papers by F. Anthony Greco Breakdown of academic impact, for papers by Thierry Philip Breakdown of academic impact, for papers by Richard Sposto Breakdown of academic impact, for papers by Maria Alma Rodriguez Breakdown of academic impact, for papers by Andrew Jack
Rankless by CCL
2026